Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase Year-over-Year Fiscal Year 2022 EBITDA of $17.8 million, Represented Margins of 14%, and a 3x Increase Over Fiscal Year 2021 Recorded Highest Annual Operating Cash Flow in […]
Rehovot, Israel, and Hoboken, NJ – March 15, 2023 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear […]
• FDA Approval Currently Expected by Mid-2023 • Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50% • Ability to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency Rehovot, Israel, and Hoboken, NJ – January 4, 2023 — Kamada Ltd. (NASDAQ: KMDA; TASE: […]
Rehovot, Israel, and Hoboken, NJ – December 19, 2022 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that its Chief Financial Officer (CFO), Chaime Orlev, will transition out of his role to pursue other opportunities, effective March 15, 2023, following the expected filing […]
Third Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG Portfolio Strong Results Represent Completion of the Company’s Strategic Transformation into a Diversified Commercial Entity with Multiple Growth Drivers Adjusted EBITDA for the Third Quarter was $6.0 Million, or 19% Margin, and for […]
Trial Recruitment Beginning to Accelerate; 30 Patients Enrolled and Treated to Date. Independent Data Safety Monitoring Board (DSMB) Recommends Study Continuation Without Modification for Fourth Time Since Study Initiation. Based on Encouraging Safety Observed to Date, Trial Inclusion Criteria Revised to Also Include Patients with Severe Airflow Limitation, Thereby Expanding Potential Patient Treatment Population. Company […]
REHOVOT, Israel, and Hoboken, NJ, – October 26, 2022 – Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 – […]
• Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021. • Supply Extension Secures Ongoing Sales of Approximately $7.5 Million Per Year for 2023-2025, with an Option to Extend for up to Additional Two Years. Rehovot, Israel, and Hoboken, NJ, October 19, 2022 – Kamada Ltd. […]
Second Quarter 2022 Revenues were $23.6 Million; First Half 2022 Revenues of $51.7 Million Increased 5% Year-Over-Year First Half 2022 Adjusted EBITDA of $4.6 Million; Excluding Labor Strike Related Loss, Adjusted EBITDA Totaled $8.0 Million, Representing Adjusted EBITDA Margins of 15% of First Half 2022 Revenues Generated Operating Cash Flows of $16.4 Million in First […]
Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin America Product Supply Expected During the Fourth Quarter of 2022 and the First Half of 2023 Rehovot, Israel, and Hoboken, NJ, July 6, 2022 — Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty […]